Halifax
I will be very surprised if Consort end up buying Ams, I believe that this might bring some others to the party. Kimberley Clark is one. I do hope that this is not sold cheap.

stable yes looking at Consort's financials AMS is quite large for them to swallow although they did takeover Medical House late last year,not sure there is much synergy either.

ams finals look good, promise of 1st divi next year is in the hope of attracting institution interest.
No news re the 'bid' nor anything re kc trial results
still have to wait, if not before, hope for more info at agm.
also good report on current year trading

Todays agm statement looks bullish

Bring to the top monthly although i do seem to be the only one interested.

Bring to the top

And another high or breakout.

and another

repeat in error

I am sure there are a few dormant followers of advanced medical. Just to remind you that 1/2 year figures due Wednesday.Today's activity suggests that many want to be long before the results. The talk from management re the future trading for the year is the key to continuing upside.

Results this morning,show continuing growth.
How long before serious large company decides to take this in house?
I do not want this to happen short term as more growth to be had.

another high today finished plus 3 but was plus 5 at one time.

another up day as bid finished another 2p higher . Price has now more than doubled in past year.
Todays volume over 15 mill as some big players switching about.

small rise this am
plus1p
first added to this thread 28th Oct 2009 , price was 29p.
Last time any one else added to thread 26th Feb was 33.50
now 60 bid
I do hope that many have been in for the ride , as I expect it may well go higher, although at a slower pace as price gets closer to true value.

plus 3 p today another high, 66 bid 68 offered, I am away after tomorrow so someone else may well keep you all up to date.

doom , doom, its down 2 p today, no news,its the end of the world,and I will continue to hold.

Nobody else seems to be interested, I may be lonely but AMS continues to shine.
71.5 bid today on high volume.I do not like those that forecast market prices in the near future, but my worry is that one of the big medical houses will come along offering the money before the market realises just what this company is worth.
Why should I worry, I seem to be the only one here.

You are not alone, I'm completely with you having held shares for a few months now after a bid for the company was rejected and a higher bid did not materialise but the potential prospects were there for the company to get recognition by the City - perhaps that is beginning to happen now as I cannot see any substantial news at present to send the price on an upward spiral but long may it continue

mogkins

sorry to not to have noticed your comment before today.
I am sure that there are more than we two here but most are very bashful.
with 19 mill share trade over the past few days against an normal 2/300 k per day I am awaiting news. Some old hands are suspecting an agreed bid, I do not know other than we should be seeing an flag soon as the volume trade against the 145 mill issued must call for somebody to admit there holdings have changed.
The house broker kept away as the price jumped last week, now he is on the fringe.
Interesting times, but must stop guessing

This morning we have ourselves a breakout to a new high by the looks of it.



Recent article at proactiveinvestors.com:

Thursday, October 21, 2010

Advanced Medical Solutions sets its sights on the US
by Ian Lyall

WHAT do silver and super-glue have in common?

No idea? Well, the answer is they are the cornerstones of growth for wound-care company Advanced Medical Solutions (LON:AMS).

Silver is the infection retarding agent the company uses in the SilverCel range of dressings, while it also produces and sells super-glue. But not the type you might use to fix broken crockery.

Instead it is the sort of adhesive that instantly knits cuts back together and is marketed as LiquiBand.

But lets back up a little and find out exactly what AMS does.

Its in the market for advanced wound-care so not the bog-standard bandages and plasters you might find in the first aid kit.

Mainly its products are used for chronic wounds, which might have become infected and require a special dressing.

Its range divides into two categories - foams and fibres - which are sold through a network of major suppliers.

However it also has a budget brand which it distributes through private label partners and markets direct to the NHS. Well hear more about this later.

AMS has a small bite of the advanced wound-care market, which is conservatively estimated to be worth US$3.6 billion and which is currently dominated by a handful of bigger players.

It means the group sits under the radar of industry giants such as Smith & Nephew, Systagenix and ConvaTec, which allows it to nibble away at the trios slice of the cake.

The intellectual property that makes its dressings stand out in the marketplace is protected by around 70 separate patents, while the group is able to refresh the offering thanks to a keen focus on research and development.

The recent interim results, meanwhile, show the group is expanding at quite a rate of knots.

Revenues advanced by 47 per cent year-on-year to 14.5 million in the six months to June 30, or 25 per cent if the contribution of Corpura, the recently acquired foams business, is excluded.

Pre-exceptional profits grew 136 per cent to 2.1 million, while AMS generated 1.4 million of cash in the period.

And unlike many of the small and growing firms in the healthcare sector it is even pledging to pay a dividend.

The plan is to hand over 10 per cent of post tax earnings initially and then progressively grow the payout after that.

We are still very much a capital growth stock, says Dr Don Evans, chief executive.

But we do believe paying a dividend is a good discipline.

We have a very good institutional, private client and retail investor base. And even the institutions think paying a dividend is a good thing. It shows we have grown up.

Investec predicts pre-tax profits this year will hit 5.1 million this year and advance to 6.3 million in 2011.

Over the past five years it has built a 20 per cent market share in silver products, sold through Systagenix and other partners, and AMS wants to build on this number two position.

We can continue to grow share, says Evans.

Meanwhile, the acquisition of the outstanding 50.6 per cent stake in Dutch company Corpura a year ago gives it a very strong position in the market for foam dressings and a platform on which to challenge the opposition. The integration has gone very well, Evans confirms.

He holds out high hopes for LiquiBand, the super-glue, whose launch in the US could transform the companys sales and earnings profile.

It is up against Dermabond, made by a J&J company, which accounts for 90 per cent of all glues sold.

Evans says the group will go in with a faster setting, slightly cheaper product.

The revenue split with partners Cardinal Healthcare and McKesson provides the sales staff and the respective companies with a very good incentive to promote LiquiBand to hospitals and doctors offices.

The hope is to build an around 20 per cent share of the 155 million-a-year glues market, establishing the same sort of base it has created for other products.

We have been beavering away in the UK and Europe with LiquiBand, Evans says. "But we clearly want to get into the US."

We have taken the past three years to work through the regulatory process, which has been quite tortuous. But we got there. And we are taking two products in the US market.

If we can do a good job with our products we can really penetrate the market.

Another growth channel is the budget range ActivHeal - which plays directly to cost-constrained healthcare providers such as NHS trusts.

The products do the job technically of their big branded equivalents, but offer a big saving typically 40 per cent, says Evans.

So we can go to an NHS trust and they are spending a certain amount of their budget on advanced wound care. So for routine wounds, straightforward wounds we can offer theme a range that does the job and saves them a chunk of money.

Then if it is a difficult wound, an infected wound they can then afford the higher value products.

That message is resonating very well at the moment because of the pressure on the NHS. The problem is theres not central decision-making so you have to do it trust by trust.

It is an incremental build. That business was up 20 per cent in the first half. But we are only in half the NHS trusts at the minute.

Recently the group has moved into one single facility at Winsford in the north west, which has the potential to treble the firms capacity giving a measure of Evans ambition.

The chief executive also believes he can deliver operational benefits from the new site that ought to drop to the bottom line. And with 24m off- balance sheet tax losses AMS is not expecting to pay tax for a few years yet.

The capital spending programme, the payment of a dividend and expenditure on R&D still leaves the company with enough cash to fund bolt-one acquisitions.

However, if Evans and his team want to do something more ambitious they will have to return to the market for additional funding, the chief executive admits.

We have got options. But we have enough to drive the organic business, he adds.

But we are mindful of the opportunities. We have a strong organic story, we dont need to do M& but it is the classic case that if we see something that is a good strategic fit and accelerates growth, we will do it.



AMS At a Glance

TICKER LON:AMS

Market Cap: 100 million

Sector: Healthcare (advanced wound-care)

Employs 240 people in Winsford, Plymouth and the Netherlands

Latest results: H1 2010 pre-tax profits of 2.1 million, up 136 per cent

juzzle
Good article 3 weeks old.
What caused todays rise after period of calm?????